<DOC>
	<DOCNO>NCT00357318</DOCNO>
	<brief_summary>This phase I trial study side effect best dose bevacizumab sunitinib treat patient solid tumor . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Sunitinib may stop growth tumor cell block enzymes need cell growth . Bevacizumab sunitinib may also stop growth tumor cell block blood flow tumor . Giving bevacizumab together sunitinib may kill tumor cell .</brief_summary>
	<brief_title>Bevacizumab Sunitinib Treating Patients With Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose bevacizumab combination sunitinib malate ( SU11248 ) patient solid tumor . SECONDARY OBJECTIVES : I . Evaluate objective response rate , time disease progression , overall survival patient . OUTLINE : This multicenter , dose-escalation study . Patients receive bevacizumab IV 30-90 minute day 1 , 15 , 29 oral sunitinib malate ( SU11248 ) daily day 1-28 . Courses repeat every 42 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos bevacizumab SU11248 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 10 patient treated MTD . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven metastatic/unresectable adrenocortical carcinoma melanoma amenable curative surgical radiation therapy . Accrual close 5/27/2009 patient renal cell carcinoma No squamous cell histology No histology close proximity major blood vessel No history know brain metastasis , spinal cord compression , carcinomatous meningitis No new evidence brain leptomeningeal disease screen CT scan MRI ECOG performance status ( PS ) 01 OR Karnofsky PS 60100 % AST ALT ≤ 2.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Creatinine ≤ 1.5 time ULN Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥100,000/mm³ Hemoglobin ≥ 10.0 g/dL Calcium ≤ 12.0 mg/dL Urine protein : creatinine ratio ≤ 0.5 urinalysis Patients urine protein : creatinine ratio &gt; 0.5 must proteinuria &lt; 1,000 mg 24hour urine collection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ≥ 6 month completion study therapy None follow within past 12 month : Myocardial infarction Severe/unstable angina Severe peripheral vascular disease ( claudication ) procedure peripheral vasculature Coronary/peripheral artery bypass graft New York Heart Association ( NYHA ) grade IIIIV congestive heart failure Cerebrovascular accident transient ischemic attack Clinically significant bleed Deep venous thrombosis Pulmonary embolism No ongoing cardiac dysrhythmias NCI CTCAE ≥ grade 2 , atrial fibrillation grade , prolongation QTc interval &gt; 450 msec ( male ) &gt; 470 msec ( female ) No history serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ≥ 3 beat row ) No condition classify NYHA grade III IV No hypertension control medication Blood pressure &lt; 140/90 mm Hg No evidence bleed diathesis coagulopathy No history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 28 day No history know brain metastasis , spinal cord compression carcinomatous meningitis , new evidence brain leptomeningeal disease screen CT MRI scan unless without progression * MRI CT 3 month . '' No significant traumatic injury within past 28 day No serious , nonhealing wound , ulcer , bone fracture No known hypersensitivity Chinese hamster ovary cell product recombinant human antibodies No known HIV AIDSrelated illness No severe acute chronic medical psychiatric condition laboratory abnormality would preclude study participation . Recovered prior radiation therapy , surgery , prior therapy No prior bevacizumab sunitinib malate ( SU11248 ) Other antiangiogenic therapy allow No prior tyrosine kinase inhibitor VEGF receptor bevacizumab patient metastatic renal cell carcinoma No major surgical procedure open biopsy within past 28 day No core biopsy within past 7 day No radiation therapy systemic therapy within past 4 week No concurrent fulldose anticoagulant ( e.g. , warfarin ) Concurrent lowdose anticoagulation ( e.g. , prophylactic port patency ) allow No concurrent treatment another clinical trial No concurrent investigational drug No concurrent major surgery No concurrent anticancer agent therapy , include chemotherapy , biological response modifier , hormonal therapy , surgery , palliative radiation therapy , immunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>